Sandoz Entered into an Agreement with Just - Evotec Biologics to Develop and Manufacture Multiple Biosimilar
Shots:
- The companies collaborated to develop and manufacture multiple biosimilar products. Evotec receives an up front, ~$640M upon the achievement of the development progress & also receives additional fees based on commercial manufacturing progress.
- Sandoz gets the access to Just-Evotec Biologics’ drug substance development platform and manufacturing technology enabling Sandoz to expand its existing biosimilars pipeline from 15 to ~24 candidates
- Additionally, Sandoz aims to enhance its early-stage biosimilar pipeline through this collaboration. The collaboration also provides an opportunity to enhance integrated development and manufacturing network
Ref: Novartis | Image: Sandoz
Related News:- Sandoz Reports the EMA Acceptance of MAA for Proposed Biosimilar Denosumab
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
